Immunotherapeutic vaccines developer Imcyse is set to initiate the Phase Ib clinical trial of Imotopes for the treatment of insulin-dependent (type 1) diabetes, following the authorisation from the regulatory authorities of Belgium and the UK.
Developed using the firm’s Imotopes technology, which blocks the immune cells that destroy the insulin-producing beta cells in the pancreas, Imotopes are specific modified peptides that activate a new type of T-cell called cytolytic T-cells.
The use of a specific Imotope is claimed to block the altered immune response involved in the destruction of the pancreas.
The Phase Ib trial is to be performed at 18 clinical sites across Belgium, France, Germany, the UK and Denmark, and will enrol patients who were diagnosed within six months before their recruitment.
Imcyse CEO Pierre Vandepapelière said: “The start of the clinical trial for this product is a major milestone for Imcyse and a recognition by the regulatory authorities of the quality of the data generated by our team.
“Imcyse aims to develop treatments to halt the disease process when the first signs of autoimmune disease emerge, thereby preventing the development of the disease and the onset of complications.”
According to the data from preclinical studies, a prolonged effect was observed after a few subcutaneous injections of Imotopes.
The trial is being conducted in partnership with the French National Institute of Health and Medical Research (INSERM) and is under the EXALT programme supported by the European Union’s Seventh Framework Programme for Research and Technological Development.